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A generic medicine is a pharmaceutical product intended to
be interchangeable with the originator, manufactured
without a licence from the innovating company and mar-
keted after expiry of a patent or other exclusivity rights [1].
In principle, a generic medicine should be marketed
without a commercial brand name, under the International
Non-proprietary Name (INN). However, the definition of
generic medicine is not always precise, as it is still more a
commercial than a legislative concept in many countries.
Copies of branded drugs have been marketed for dec-
ades in many countries; however, laws in the last century
such as the Hatch-Waxman Act in the US, have made it
much easier and cheaper to bring a new generic drug to
market without undermining its quality, safety and effica-
cy. In Europe, an abbreviated procedure—the abridged
application defined by directive 87/21/EEC—is permitted
under certain circumstances, therefore generic manufac-
turers merely have to prove that their drugs have the same
active ingredients and perform in the same way as the
branded drugs.
The first article [2] of this supplement confirms that the
regulatory definition of generics is still inconsistent and
piecemeal throughout the world. To warrant the full inter-
changeability of generics with originators, their definition
should include the requirements for bioequivalence. Un-
fortunately, important differences in the terms used for
generic drugs, such as similars, copies, branded generic
products, etc., are still found among countries worldwide.
These differences and inconsistencies can challenge the
trust of local people and must be addressed and recognised,
particularly in developing countries. The second article [3],
focused on the Chinese market (one of the most important
in the world), shows a very important example of the
problems raised by the lack of a clear cut definition of
generics in the biggest developing country. It describes a
confusing array of drug categories and a lack of quality
assurance for generics that could easily be avoided by
copying the regulation of developed countries.
A crucial problem for generics is the guarantee on safety
and quality of products marketed. Although evidence of
bio-equivalence is important, national health authorities
should set up mechanisms for checking manufacturing
practice by (local and foreign) providers too. However,
safety and quality problems should be less of a threat than
in the past, at least in developed countries where the few
manufacturers (including the ‘‘sister companies’’ of some
‘‘big pharma’’) in the generics market are definitely inter-
ested in avoiding risky practices that could dramatically
undermine their image [1]. A peculiar issue brought up in
many comments is the distrust of generics due to the high
potential for counterfeits in developing countries. Howev-
er, this argument hardly matters for generics specifically,
since counterfeiters are much more likely to go after the
higher priced, branded drugs that would offer revenues far
exceeding those made by forging much cheaper generics.
Once these basic issues have been addressed, the impact
of generic substitution on health and economic outcomes,
analysed in the third article [4], would be negligible and its
debate pointless. Once it is guaranteed that both originators
and generics use an approved and identical active ingre-
dient with a similar bioavailability, the outcomes should be
identical and therefore there is no reason to think that
generics could end up costing more than their branded
equivalent products.
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Nevertheless, despite representing over half of the total
volume of pharmaceutical products used worldwide [5],
scepticism about generics is still widespread, often inspired
by adverse economic interests. In general, most pharma-
ceutical companies have an obvious interest in discrediting
generics and undermining their credibility among physi-
cians [6], who in turn are reluctant to favour the wide-
spread prescription of generics without any financial
incentive by health authorities. In principle, community
pharmacists are more open to using generics. Their interest
depends on whether commercial discounts offered by
generics manufacturers can compensate their lower mar-
gins (compared to originators) and the extra time needed to
inform patients.
The last article [7] shows that the attitude of physicians
and pharmacists towards generics still varies a lot world-
wide, even between Northern and Southern European
countries. In the Nordic countries trust in the quality of
generics is higher than that in the Southern countries, with
concerns only over their taste, packaging and appearance,
since this may affect patients’ understanding and accep-
tance. A common concern, in particular for vulnerable
patient groups (eg, elderly patients with polypharmacy or
with dementia), is the confusion and problem of adherence
when switching to generics. However, this drawback could
be easily tackled by recommending that generic manufac-
turers copy not only the active ingredients, but also the
originators’ excipients and packaging, in order to safeguard
the ‘‘placebo effect’’ on generic drugs too. Furthermore, to
streamline communication, INN prescribing should be-
come mandatory and physicians and pharmacists should be
educated on chemical names at the start of their training.
Another issue that does not help strengthen patients’
trust in generics is the adoption of the so-called ‘‘reference
pricing’’ (RP) scheme, whereby health authorities set a
maximum price for products that have the same active
ingredient and the cost of using equivalent products that
exceed this RP has to be covered by the patient [8]. This
scheme, originally adopted in Germany, has been taken in
many continental European countries with little resistance
from the pharmaceutical industry, allowing companies
some freedom in pricing their competing off-patent prod-
ucts. However, RP may raise concern among the general
population on the real equivalence of drugs in the long
term, which is often affected by the interests of physicians
and pharmacists as previously discussed. The underlying
and emerging message that cheaper generics are like ‘‘hard
discount’’ low-quality products in mass markets compared
with originators and so patients should be willing to pay
more for ‘‘brand’’ products is simply false: generic drugs
are equivalent to originators, so a price difference can
hardly be justified on reimbursed drugs.
To conclude, although off-patent drugs have been in use
for many years by definition and both their efficacy and
adverse events are well known, their generic versions are
still often debated, with their safety and efficacy compared
with their originators continually questioned. This is hard
to accept, particularly in developed countries that for
decades have had clear rules in place on the characteristics
of generics. Promoting prescription by INN and increasing
downward pressure on prices of off-patent drugs are ar-
guably useful tools to save on money that can be used in
other ways, eg, for financing innovative drugs. Particularly
in this period of financial crisis that hits both developed and
developing countries, health authorities should use all
means possible to constrain their budgets and generics are
of utmost importance in trying to keep pharmaceutical
expenditure sustainable.
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